Cited by 75Heart Failure Treatment and ManagementChronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Worsening Renal Function and Outcome in Heart Failure Patients with Reduced and Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment: Data from the CHARM-Study Programme

Open access
Damman, Kevin, Solomon, Scott D., Pfeffer, Marc A., Swedberg, Karl, Yusuf, Salim, Young, James B., Rouleau, Jean L., Granger, Christopher B. +1 more·2016·European Journal of Heart Failure

Abstract

Aims: We investigated the association between worsening renal function (WRF) that occurs during renin–angiotensin–aldosterone system inhibition initation and outcome in heart failure (HF) patients with preserved ejection fraction (HFPEF) and compared this with HF patients with reduced ejection fraction (HFREF). Methods and results: We examined changes in estimated glomerular filtration rate (GFR) and the relationship between WRF (defined as ≥26.5 µmol/L and ≥25% increase in serum creatinine from baseline to 6 weeks) and outcome, according to randomized treatment, in patients with HFREF (EF <45%; n = 1569) and HFPEF (EF ≥45%; n = 836) in the CHARM programme. The primary outcome was cardiovascular death or HF hospitalization. Estimated GFR decreased 9.0 ± 21 vs. 4.0 ± 21 mL/min/1.73 m2 with candesartan and placebo, respectively, and this was similar in HFREF and HFPEF. WRF developed more frequently with candesartan, 16% vs. 7%, P < 0.001, with similar findings in patients with HFREF and HFPEF. WRF was associated with a higher risk of the primary outcome: multivariable hazard ratio (HR) 1.26, 95% confidence interval 1.03–1.54, P = 0.022, in both treatment groups, and in both HFREF and HFPEF (P for interaction 0.98). In HFREF, WRF was mostly related to HF hospitalization, while in HFPEF, WRF seemed more associated with mortality. Conclusions: GFR decreased more and WRF was more common with candesartan compared with placebo, and this was similar in HFREF and HFPEF. WRF was associated with worse outcomes in HFREF and HFPEF. Although no formal interaction was present, the association between candesartan treatment, WRF, and type of clinical outcome was slightly different between HFREF and HFPEF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.609

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous studies have shown that worsening kidney function identified by even modest increases in creatinine (or equivalent reductions in eGFR) is associated with worse cardiovascular outcomes in patients with HFrEF.

    “The reduced risk of doubling of creatinine concentration is notable, given that previous studies have shown that worsening kidney function identified by even modest increases in creatinine (or equivalent reductions in eGFR) are associated with worse cardiovascular outcomes in patients with HFrEF.3,17,18,22”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Damman, K., Solomon, S. D., Pfeffer, M. A., Swedberg, K., Yusuf, S., Young, J. B., Rouleau, J. L., Granger, C. B., & McMurray, J. J. V.
Affiliations
  • University Medical Center Groningen (NL)
  • Brigham and Women's Hospital (US)
  • University of Gothenburg (SE)
  • Population Health Research Institute (CA)
  • Cleveland Clinic (US)
  • Université de Montréal (CA)
  • Duke Medical Center (US)
  • University of Glasgow (GB)
Corresponding author
Damman, Kevin
Venue
European Journal of Heart Failure
Published
2016-07-18
Volume
18
Issue
12
Pages
1508-1517
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2491534867
Cited by
75
References
25
Citations by year
2026: 2 · 2025: 4 · 2024: 10 · 2023: 5 · 2022: 9 · 2021: 6 · 2020: 8 · 2019: 7 · 2018: 11 · 2017: 8 · 2016: 4 · 2014: 1
FWCI
8.26
Type
journal article
Language
en
Open access
Locations
  • European Journal of Heart Failure (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • Research Bank (Australian Catholic University) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
  • Netherlands Heart Institute
  • ESC Heart Failure Association Research Grant
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
worsening renal function, heart failure, preserved ejection fraction, reduced ejection fraction, angiotensin receptor blockers, candesartan, renin-angiotensin-aldosterone system inhibition, estimated glomerular filtration rate, serum creatinine, cardiovascular mortality, heart failure hospitalization
MeSH terms
Aged, Benzimidazoles, Biphenyl Compounds, Creatinine, Female, Glomerular Filtration Rate, Heart Failure, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Multivariate Analysis, Logistic Models, Proportional Hazards Models, Randomized Controlled Trials as Topic, Disease Progression, Renal Insufficiency, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review